Country Overviews: market research reports

... understand world medical marketplaces, and be able to answer quickly those questions that arise daily, is essential. That is why this current and comprehensive market statistics source is an invaluable aid for every executive. ...  |  read more...

... prompt local companies to get more involved in the segment. According to data published by Swissmedic, Sandoz Pharmaceuticals, Novartis's generic medicines arm, has 556 preparations locally approved, while Teva has 345 preparations locally approved. However, ...  |  read more...

... 2016, the Malaysian drug market, valued at around MYR5.55bn (US$1.81bn) in 2011, is expected to post a compound annual growth rate (CAGR) of 9.4% in local currency terms, driven primarily by the expansion and modernisation ...  |  read more...

... (IP) rights. The economy remains resilient, despite the problems in the nearby eurozone, although weaker-than-expected oil prices remain a concern. The government appears set to retain continuity in fiscal and economic policy, and the country’s ...  |  read more...

... and the critical issues faced by the healthcare industry in 2011, as well as the factors that will influence ICT investment decisions over the next few years. Overall, 2011 ICT spending by the healthcare sector ...  |  read more...

... restructuring of the public healthcare system. The policy also fails to address current healthcare concerns, which include rising costs, long hospital waiting times and a lack of beds. For the time being, we hold to ...  |  read more...

... in the first quarter of 2012 highlight that the general weakness in its macroeconomic has not filter down to the sector and instead the sector performance will largely hinge on the country’s healthcare reform plans ...  |  read more...

... the country still has some way to go in terms of legislating for a dynamic healthcare industry, and political stalemate is hindering progress. Headline Expenditure Projections Pharmaceuticals: KWD204mn (US$737mn) in 2011 to KWD216mn (US$771mn) in ...  |  read more...

... challenging economic situation will hamper the purchase of necessary medicines by the majority of the cash-strapped population, especially as out-of-pocket contribution to healthcare in general stands at almost 40%. We therefore envisage generic medicines gaining ...  |  read more...

... in place over the coming decade, epidemiological and demographic pressures will combine to increase the need for cost-containment in regards to public spending. Nevertheless, Bahrain’s pharmaceutical market growth is expected to remain ahead of its ...  |  read more...

... the French medicines agency (Afssaps).We note that this aligns with our core view that dialogue between firms, regulators and payers will become more common as the communication of product value becomes increasingly important. Regulatory agencies ...  |  read more...

... to contagion from the European Union (EU)’s economic crisis as indicated by slowing economic growth in Q112. Continued lack of investment in the healthcare system translates into a pharmaceutical market driven by out-of-pocket purchasing and ...  |  read more...

Critical information and statistics on national and regional health infrastructure and provision. An essential source of detailed key business data on this fast growing economy.  |  read more...